Choriocarcinoma is a highly malignant, fast-growing form of gestational trophoblastic disease. It develops from the placental trophoblast tissue after any type of pregnancy, though it arises most frequently following a complete hydatidiform mole. Unlike normal placental tissue, choriocarcinoma invades the myometrium deeply, destroys local blood vessels, and metastasizes early through the bloodstream to distant organs like the lungs and brain.
While it can follow a normal term delivery, miscarriage, or ectopic pregnancy, about half of all cases stem from a preceding molar pregnancy. The abnormal proliferation of trophoblastic cells creates soft, hemorrhagic masses in the uterine cavity. Because it produces high levels of human chorionic gonadotropin, monitoring this hormone is crucial for early detection in high-risk patients following evacuation of a mole.
Midwives must maintain a high index of suspicion for choriocarcinoma when a patient reports persistent or irregular vaginal bleeding weeks after any pregnancy event. The bleeding is often accompanied by uterine subinvolution, where the uterus remains larger and softer than expected for the postpartum timeline.
If the disease has spread, symptoms will reflect the secondary sites involved. Lung metastasis can cause a chronic cough, shortness of breath, or hemoptysis. Brain involvement may present with severe headaches, dizziness, or focal neurological deficits. Pelvic pain and a tender, enlarged mass felt during bimanual examination are also common local signs.
Diagnosing choriocarcinoma relies heavily on a combination of hormone assays, imaging studies, and tissue pathology when accessible.
Choriocarcinoma is one of the most chemo-sensitive malignancies known in medicine, meaning chemotherapy forms the absolute cornerstone of treatment. Even in cases with widespread metastasis, cure rates remain exceptionally high with appropriate drug regimens.
Single-agent chemotherapy, such as methotrexate or actinomycin-D, is typically used for low-risk disease. Multi-agent chemotherapy combined with selective pelvic surgery or radiation is reserved for high-risk metastatic cases. Hysterectomy may be performed in older women who have completed their family or to control life-threatening hemorrhage from a refractory uterine tumor, but preserving fertility is often achievable with chemotherapy alone in younger patients.
Caring for a patient with choriocarcinoma extends beyond administering medications. Midwives provide essential emotional support, as a cancer diagnosis following a pregnancy loss brings profound grief and anxiety.
Rigorous post-treatment surveillance is mandatory. Patients must be counseled to avoid a new pregnancy for at least one year by using reliable contraception, usually barrier methods or oral contraceptive pills. This waiting period ensures that any future rise in hCG levels indicates a recurrence of choriocarcinoma rather than a normal new pregnancy, protecting both maternal health and diagnostic clarity.